Navigation Links
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Date:10/9/2009

ements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of streamlining review attributed to Fast Track Designation, the timing of clinical trials and development efforts and the results of clinical and pre-clinical studies are all forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... -- GenomeDx Biosciences today announced that a new study ... test for prostate cancer, was able to predict rapid ... prostatectomy without adjuvant therapy. Although rapid metastasis in men ... genomics to identify these men who have a highly ... The study has been published online by the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... LA JOLLA, Calif., May 12 TorreyPines,Therapeutics, Inc. (Nasdaq: ... a conference call and audio webcast on Tuesday, May ... with the release of its,financial results for the first ... results at 7:30 a.m. ET on Tuesday, May,13, 2008., ...
... and its biotech ... pipeline, ... today completion of the final phase of its $1 billion,effort to further ... its Indianapolis operations, Lilly officials, along,with participation by Indianapolis Mayor Gregory Ballard, ...
... screening initiative launches in Atlanta and continues for 90 days;, ... in 13 cities ... across the country, ... specialty biopharmaceutical company, today,announced the launch of a 13-city mobile screening ...
Cached Biology Technology:TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 2Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... paleontological evidence as a crystal ball, 18 scientists, including ... much worse collision course with Mother Nature than currently ... Earth,s biosphere, a paper just published in Nature ... disciplines, suggest our planet,s ecosystems are careening towards an ...
... Working with researchers at the University of Pittsburgh ... Barbara have found high levels of beneficial omega-3 fatty ... woman as compared to women in the United States. ... journal Maternal and Child Nutrition . The ...
... A team of George Washington University researchers have received ... nuclear reactor cores. The findings of the research have ... the future. Philippe M. Bardet, assistant professor of ... project, and his colleagues, Elias Balaras, associate professor of ...
Cached Biology News:Study predicts imminent irreversible planetary collapse 2UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women 2Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors 2
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Human Siglec-9 Biotinylated Affinity Purified Pab...
Human MFRP MAb (Clone 291218)...
Biology Products: